JMP Securities Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $66 to $68.
June 18, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reaffirmed its Market Outperform rating on Mirum Pharmaceuticals and increased the price target from $66 to $68, indicating confidence in the company's future performance.
The reaffirmation of the Market Outperform rating and the increase in the price target by JMP Securities suggest positive sentiment and confidence in Mirum Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100